Gemcitabine Combination Nano Therapies for Pancreatic Cancer.

Published on Nov 4, 2019in Pharmaceutics4.421
· DOI :10.3390/PHARMACEUTICS11110574
Kamalika Samanta2
Estimated H-index: 2
(UTHSC: University of Tennessee Health Science Center),
Saini Setua7
Estimated H-index: 7
(UTHSC: University of Tennessee Health Science Center)
+ 3 AuthorsSubhash C. Chauhan49
Estimated H-index: 49
(University of Texas at Austin)
Sources
Abstract
Pancreatic cancer is one of the deadliest causes of cancer-related death in the United States, with a 5-year overall survival rate of 6 to 8%. These statistics suggest that immediate medical attention is needed. Gemcitabine (GEM) is the gold standard first-line single chemotherapy agent for pancreatic cancer but, after a few months, cells develop chemoresistance. Multiple clinical and experimental investigations have demonstrated that a combination or co-administration of other drugs as chemotherapies with GEM lead to superior therapeutic benefits. However, such combination therapies often induce severe systemic toxicities. Thus, developing strategies to deliver a combination of chemotherapeutic agents more securely to patients is needed. Nanoparticle-mediated delivery can offer to load a cocktail of drugs, increase stability and availability, on-demand and tumor-specific delivery while minimizing chemotherapy-associated adverse effects. This review discusses the available drugs being co-administered with GEM and the limitations associated during the process of co-administration. This review also helps in providing knowledge of the significant number of delivery platforms being used to overcome problems related to gemcitabine-based co-delivery of other chemotherapeutic drugs, thereby focusing on how nanocarriers have been fabricated, considering the modes of action, targeting receptors, pharmacology of chemo drugs incorporated with GEM, and the differences in the physiological environment where the targeting is to be done. This review also documents the focus on novel mucin-targeted nanotechnology which is under development for pancreatic cancer therapy.
Download
📖 Papers frequently viewed together
9 Citations
10 Citations
8 Citations
References98
Newest
#1Keyang Qian (Nanjing Medical University)H-Index: 2
#2Hanqing Qian (NU: Nanjing University)H-Index: 18
Last. Baorui Liu (NU: Nanjing University)H-Index: 44
view all 6 authors...
Abstract Gastric cancer, one of the most common disease, has become a major public health problem worldwide. Cisplatin (DDP) has been a widely used drug for the treatment of cancer, also usually applied in gastric cancer in clinic. However, the side effects including toxicity and drug-resistance restricted the usage of DDP in clinic, so we prepared a DDP-complexed hydrogel (DDP-Gel) and investigated its efficacy in gastric cancer. For in vivo studies, MKN45-Luc cells were injected into BLAB/C no...
2 CitationsSource
#1Chiara Bastiancich (UCL: Université catholique de Louvain)H-Index: 11
#2Elia Bozzato (UCL: Université catholique de Louvain)H-Index: 3
Last. Véronique Préat (UCL: Université catholique de Louvain)H-Index: 79
view all 6 authors...
Abstract Lauroyl-gemcitabine lipid nanocapsules (GemC12-LNC) hydrogel, administered intratumorally or perisurgically in the tumor resection cavity, increases animal survival in several orthotopic GBM models. We hypothesized that GemC12-LNC can be used as nanodelivery platform for other drugs, to obtain a combined local therapeutic approach for GBM. Paclitaxel (PTX) was selected as a model molecule and PTX-GemC12-LNC formulation was evaluated in terms of physicochemical and mechanical properties....
15 CitationsSource
#1Prashanth RawlaH-Index: 15
#2Tagore Sunkara (Mercy Medical Center (Baltimore, Maryland))H-Index: 13
Last. Vinaya GaduputiH-Index: 9
view all 3 authors...
Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. However, its toll is higher in more developed countries. Reasons for vast differences in mortality rates of pancreatic cancer are not completely clear yet, but it may be due to lack of appropriate diagnosis, treatment and cataloging of cancer cases. Because patients seldom exhibit symptoms until an advanced stage of the disease, pancreatic cancer remains one of the most lethal malignant neoplasms that caused 432,2...
381 CitationsSource
#1Mandana Emamzadeh (UCL: University College London)H-Index: 3
#2Mina Emamzadeh (UCL: University College London)H-Index: 2
Last. George Pasparakis (UCL: University College London)H-Index: 17
view all 3 authors...
Although combinational anticancer chemotherapies have been proven to improve the life expectancy of patients in the clinic, their full potential is severely limited by the additive toxicities of the drug molecules. Targeted drug delivery systems could alleviate this major limitation by the design of nanocarriers that can cocarry multiple drug molecules in order to augment drug synergism at the site of interest while reducing the systemic side effects. In this study, we report on a thermoresponsi...
3 CitationsSource
#1Fernando RiveraH-Index: 54
#2Manuel BenavidesH-Index: 18
Last. Marc KüngH-Index: 1
view all 6 authors...
Abstract Background Tumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with glioblastoma. This phase 2 PANOVA study was conducted to examine the combination of TTFields plus chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Methods Forty patients with newly-diagnosed, locally advanced or metastatic PDAC received continuous TTFields (150 KHz for ≥18 h/day) plus gemcitabine (1000...
14 CitationsSource
#1Maria Monica Haydock (Gloucestershire Hospitals NHS Foundation Trust)H-Index: 2
#2Saroj Sigdel (Marshall University)H-Index: 3
Last. Toni Pacioles (Marshall University)H-Index: 2
view all 3 authors...
Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus alopecia, and palmar–plantar erythrodysesthesia. Skin necrosis is a very rare adverse effect of this otherwise well-tolerated chemotherapeutic agent. In searching the literature, only one other case h...
2 CitationsSource
Histo-molecular oncogenesis of pancreatic cancer: From precancerous lesions to invasive ductal adenocarcinoma
14 CitationsSource
Liposomes, a phospholipid bilayer vesicular system is extensively being used and studied for drug delivery applications in cancer therapy. The reason behind is advantages that liposomes offer such as their biocompatible and non-immunogenic nature, improved bioavailability of anticancer drugs and versatility of efficiently encapsulating both hydrophilic and hydrophobic drugs. Recent advances such as surface functionalization and modifications of liposomes have played very crucial part to overcome...
3 CitationsSource
#1Shiliang DongH-Index: 1
#2Yuexin GuoH-Index: 1
Last. Mingzhi Zhang (Zhengzhou University)H-Index: 23
view all 10 authors...
: Traditional chemotherapeutic drugs have shown limited clinical curative effects in antitumor therapy. The application of multidrug combination and adjuvant-drug carriers is a feasible strategy to overcome the limitations while minimizing the dosage of single drug and acquiring the synergistic effects in tumor therapy. However, the systemic toxicity, drug resistance, and tumor recurrence are still unavoidable. Here we develop core-shell nanoparticles (NPs) to encapsulate paclitaxel (PTX) and ge...
8 CitationsSource
#1Sinem Yaprak Karavana (Ege University)H-Index: 14
#2Zeynep Ay Şenyiğit (Izmir Kâtip Çelebi University)H-Index: 7
Last. Esra Baloğlu (Ege University)H-Index: 14
view all 8 authors...
Introduction: Bladder cancer is responsible for more than 130,000 deaths annually worldwide. Intravesical delivery of chemotherapeutic agents provides effective drug localization to the target area to reduce toxicity and increase efficacy. This study aimed to develop an intravesical delivery system of gemcitabine HCl (Gem-HCl) to provide a sustained-release profile, to prolong residence time, and to enhance its efficiency in the treatment of bladder cancer. Materials and methods: For this purpos...
8 CitationsSource
Cited By19
Newest
#1Yongqiang HuaH-Index: 9
#2Ke ZhangH-Index: 4
Last. Luming Liu (Fudan University)H-Index: 22
view all 7 authors...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient prognosis. A cellular stress response mechanism called the unfolded protein response (UPR) has been implicated in PDAC progression. More recently, nucleobindin 1 (NUCB1), a calcium-binding protein, has been shown to control the UPR but its precise role in PDAC has not been explored. Here, we found that downregulation of NUCB1 was associated with poor prognosis in patients with PDAC. Functionally, NUCB1 overex...
Source
#1Saffiya Habib (UKZN: University of KwaZulu-Natal)H-Index: 1
#2Moganavelli Singh (UKZN: University of KwaZulu-Natal)H-Index: 21
The anti-metabolite drug gemcitabine is widely used for the treatment of a variety of cancers. At present, gemcitabine is administered as a hydrochloride salt that is delivered by slow intravenous injection in cycles of three or four weeks. Although regarded as a 'front-line' chemotherapeutic agent, its efficacy is hampered by poor target cell specificity, sub-optimal cellular uptake, rapid clearance from circulation, the development of chemoresistance, and undesirable side-effects. The use of o...
Source
#1Ajita Jindal (JNU: Jawaharlal Nehru University)H-Index: 2
Last. Aftab AlamH-Index: 7
view all 3 authors...
Immunotherapy holds great promise in overcoming the limitations of conventional regimens for cancer therapeutics. There is growing interest among researchers and clinicians to develop novel immune-strategies for cancer diagnosis and treatment with better specificity and lesser adversity. Immunomodulation-based cancer therapies are rapidly emerging as an alternative approach that employs the host's own defense mechanisms to recognize and selectively eliminate cancerous cells. Recent advances in n...
Source
#1Geetha Maniam (International Medical University)H-Index: 1
#2Chun-Wai Mai (International Medical University)H-Index: 15
Last. Ju-Yen Fu (Malaysian Palm Oil Board)H-Index: 5
view all 4 authors...
Aim: To synthesize niosomes co-encapsulating gemcitabine (GEM) and tocotrienols, and physicochemically characterize and evaluate the antipancreatic effects of the nanoformulation on Panc 10.05, SW 1990, AsPC-1 and BxPC-3 cells. Materials & methods: Niosomes-entrapping GEM and tocotrienols composed of Span 60, cholesterol and D-α-tocopheryl polyethylene glycol 1000 succinate were produced by Handjani-Vila and film hydration methods. Results: The film hydration produced vesicles measuring 161.9 ± ...
Source
#1Yuhui LiuH-Index: 3
#2Chengjian ShiH-Index: 14
Last. Renyi QinH-Index: 17
view all 13 authors...
Several natural products have been demonstrated to both enhance the anti-tumor efficacy and alleviate the side effects of conventional chemotherapy drugs. Rhein, a main constituent of the Chinese herb rhubarb, has been shown to induce apoptosis in various cancer types. However, the exact pharmacological mechanisms controlling the influence of Rhein on chemotherapy drug effects in pancreatic cancer (PC) remain largely undefined. In this study, we found that Rhein inhibited the growth and prolifer...
Source
#1Minh Thanh Vu (VAST: Vietnam Academy of Science and Technology)H-Index: 2
#1Minh Thanh Vu (VAST: Vietnam Academy of Science and Technology)H-Index: 3
Last. Dai Hai Nguyen (VAST: Vietnam Academy of Science and Technology)H-Index: 20
view all 5 authors...
In the present work, a dual-drug-loaded soy lecithin liposomal system was developed by coencapsulation of Letrozole (LET) with Paclitaxel (PTX) to improve the efficacy in breast cancer therapy. Liposomes were synthesized by the thin film layer hydration. To sufficiently evaluate the characteristics of these liposomes, the particle size, zeta potential, morphology, drug encapsulation, in vitro drug release, and cytotoxicity were ascertained. Results showed promisingly anticancer potentials, as th...
1 CitationsSource
#1Layla Mohammad-Hadi (UCL: University College London)H-Index: 2
#2Marym Mohammad-Hadi (UCL: University College London)
Abstract Minimally invasive techniques such as Photodynamic Therapy (PDT) and Photochemical Internalisation (PCI) have for years been under investigation for the treatment of solid cancers. A signi...
Source
Purpose Pancreatic cancer (PCa) is projected to become the second leading cause of cancer-related deaths by 2030. Gemcitabine (GEM) combined with erlotinib (ERL) have been approved by the FDA for locally advanced, unresectable or metastatic pancreatic cancer therapy since 2005. Type-1 matrix metalloproteinase (MT1-MMP) has been recognized as a critical mediator of several steps in PCa progression including activating TGF-β or releasing latent TGF-β from LTBP-1, resulting in increased collagen pr...
Source
#1Jing Zhou (Capital Medical University)H-Index: 1
#2Shuyan Qie (Capital Medical University)H-Index: 6
Last. Jianing Xi (Capital Medical University)H-Index: 7
view all 4 authors...
OBJECTIVE To uncover the role of microRNA-487a-3p (miR-487a-3p) in influencing the malignant development of pancreatic cancer and the involvement of its downstream target SMAD7. METHODS MiR-487a-3p level in 40 pancreatic cancer and paracancerous tissues was detected by quantitative real-time polymerase chain reaction (qRT-PCR). The relationship between miR-487a-3p level and clinical indicators in pancreatic cancer patients was analyzed. Regulatory effects of miR-487a-3p on biological phenotypes ...
2 CitationsSource
#1Natália Noronha Ferreira (UNESP: Sao Paulo State University)H-Index: 7
#2Fernanda Isadora Boni (UNESP: Sao Paulo State University)H-Index: 8
Last. Maria Palmira Daflon Gremião (UNESP: Sao Paulo State University)H-Index: 29
view all 4 authors...
Accumulating evidence has been suggesting that combining two or more anticancer drugs can provide additive or synergistic effects, improving therapeutic efficacy and delaying resistance. Nowadays, advances in nanotechnology-based delivery systems have enabled the association of different drugs into a single carrier and provided therapeutic gains to the proposed regimen. However, a new strategy also requires innovative analytical approaches that assess loading capacity, biological performance, an...
1 CitationsSource